Related Experiment Video
Updated: May 24, 2026
11:32
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumococcus infections: is the burden still as heavy?
1Département d'infectiologie, hôpital du Bocage, CHU Dijon, université de Bourgogne, Dijon, France. pascal.chavanet@chu-dijon.fr
Medecine Et Maladies Infectieuses
|March 20, 2012
Summary
Invasive pneumococcal infections decreased significantly due to antibiotics and vaccines, but incidence is rising in France. Vaccination is crucial, especially for at-risk groups, and requires regular vaccine updates.
Area of Science:
- Infectious Diseases
- Vaccinology
- Public Health
Background:
- Invasive pneumococcal infections (IPD) have seen a dramatic century-long decline in mortality, primarily attributed to antibiotics and antipneumococcal vaccines.
- However, this trend is largely confined to developed nations, with recent increases in IPD incidence observed in France across various age groups.
Purpose of the Study:
- To analyze the recent trends in invasive pneumococcal infections in France.
- To identify risk factors associated with persistent high incidence of IPD.
- To evaluate the impact of pneumococcal vaccination and inform future vaccination strategies.
Main Methods:
- Retrospective analysis of invasive pneumococcal infection incidence data in France over the last decade.
- Examination of serotype distribution changes in pediatric populations post-vaccination.
- Correlation analysis between IPD incidence and identified risk factors.
Main Results:
- Overall IPD incidence has increased in France in the past 10 years, except in children vaccinated with the heptavalent pneumococcal conjugate vaccine.
- High incidence persists in individuals with risk factors including HIV, hematologic malignancies, solid cancers, chronic lung disease, and alcohol abuse.
- A shift in serotype distribution is evident in vaccinated children, with a decrease in vaccine serotypes and an increase in related or non-vaccine serotypes.
Conclusions:
- Pneumococcal vaccination is effective, particularly in children, but the overall incidence of IPD is increasing in France.
- Targeted vaccination strategies are essential for individuals with specific risk factors.
- The observed serotype distribution changes underscore the need for regular updates to pneumococcal vaccines to maintain efficacy.
Related Concept Videos
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...